Pitfalls in laboratory monitoring of treatment in people with Haemophilia

Will Lester; Christopher Reilly-Stitt

doi:10.1016/j.blre.2022.100946

Pitfalls in laboratory monitoring of treatment in people with Haemophilia

Blood Rev. 2022 Sep:55:100946. doi: 10.1016/j.blre.2022.100946. Epub 2022 Feb 21.

Authors

Will Lester¹, Christopher Reilly-Stitt²

Affiliations

¹ Department of Haematology, University Hospitals Birmingham, UK. Electronic address: Will.lester@uhb.nhs.uk.
² UK NEQAS Blood Coagulation, Sheffield, UK.

PMID: 35248414
DOI: 10.1016/j.blre.2022.100946

Abstract

A series of cases and scenarios are described to highlight pitfalls in the interpretation of laboratory results in people with haemophilia receiving treatment. This includes assays which grossly exaggerate levels due to in vitro phenomenon and how results which over or under-estimate true values could lead to under or over treatment, unnecessary clinical concern and impact on EQA performance.

Keywords: EHL; EQA; Emicizumab; Factor; Haemophilia; Laboratory.

Publication types

Case Reports
Review

MeSH terms

Factor VIII / therapeutic use
Hemophilia A* / diagnosis
Hemophilia A* / drug therapy
Hemophilia A* / therapy
Humans

Substances

Factor VIII